GR3030131T3 - Oral liquid compositions containing paroxetine resinate - Google Patents
Oral liquid compositions containing paroxetine resinateInfo
- Publication number
- GR3030131T3 GR3030131T3 GR990401213T GR990401213T GR3030131T3 GR 3030131 T3 GR3030131 T3 GR 3030131T3 GR 990401213 T GR990401213 T GR 990401213T GR 990401213 T GR990401213 T GR 990401213T GR 3030131 T3 GR3030131 T3 GR 3030131T3
- Authority
- GR
- Greece
- Prior art keywords
- resinate
- compositions containing
- oral liquid
- liquid compositions
- containing paroxetine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
- A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9402029A GB9402029D0 (en) | 1994-02-03 | 1994-02-03 | Novel formulation |
| PCT/EP1995/000319 WO1995020964A1 (en) | 1994-02-03 | 1995-01-30 | Oral liquid compositions containing paroxetine resinate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GR3030131T3 true GR3030131T3 (en) | 1999-07-30 |
Family
ID=10749765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GR990401213T GR3030131T3 (en) | 1994-02-03 | 1999-04-30 | Oral liquid compositions containing paroxetine resinate |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US5811436A (el) |
| EP (1) | EP0742715B1 (el) |
| JP (1) | JP4445590B2 (el) |
| CN (1) | CN1074922C (el) |
| AP (2) | AP611A (el) |
| AT (1) | ATE178489T1 (el) |
| AU (1) | AU682091B2 (el) |
| BG (1) | BG62843B1 (el) |
| BR (1) | BR9507055A (el) |
| CA (1) | CA2182593A1 (el) |
| CZ (1) | CZ285128B6 (el) |
| DE (1) | DE69508924T2 (el) |
| DK (1) | DK0742715T3 (el) |
| DZ (1) | DZ1850A1 (el) |
| ES (1) | ES2129806T3 (el) |
| FI (1) | FI118205B (el) |
| GB (1) | GB9402029D0 (el) |
| GR (1) | GR3030131T3 (el) |
| HK (1) | HK1012288A1 (el) |
| HU (1) | HUT75941A (el) |
| IL (1) | IL112521A (el) |
| MA (1) | MA23441A1 (el) |
| MX (1) | MX9603203A (el) |
| MY (1) | MY113036A (el) |
| NO (1) | NO307954B1 (el) |
| NZ (1) | NZ278891A (el) |
| OA (1) | OA10446A (el) |
| PL (1) | PL178331B1 (el) |
| RO (1) | RO116342B1 (el) |
| RU (1) | RU2136281C1 (el) |
| SK (1) | SK281214B6 (el) |
| TW (1) | TW436296B (el) |
| WO (1) | WO1995020964A1 (el) |
| ZA (1) | ZA95776B (el) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6548084B2 (en) | 1995-07-20 | 2003-04-15 | Smithkline Beecham Plc | Controlled release compositions |
| US6638948B1 (en) * | 1996-09-09 | 2003-10-28 | Pentech Pharmaceuticals, Inc. | Amorphous paroxetine composition |
| US5874447A (en) | 1997-06-10 | 1999-02-23 | Synthon B. V. | 4-Phenylpiperidine compounds for treating depression |
| US6699882B2 (en) | 1998-03-24 | 2004-03-02 | Smithkline Beecham P.L.C. | Paroxetine compositions |
| DK172860B1 (da) * | 1998-03-25 | 1999-08-16 | Pharmacosmos Holding As | Jerndextranforbindelse til anvendelse som komponent i et terapeutisk middel til forebyggelse af eller behandling af jernman |
| CH689805A8 (fr) * | 1998-07-02 | 2000-02-29 | Smithkline Beecham Plc | Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant. |
| GB0003232D0 (en) * | 2000-02-11 | 2000-04-05 | Smithkline Beecham Plc | Novel composition |
| US6660298B1 (en) * | 2000-07-27 | 2003-12-09 | Pentech Pharmaceuticals, Inc. | Paroxetine tablets and capsules |
| US6720003B2 (en) | 2001-02-16 | 2004-04-13 | Andrx Corporation | Serotonin reuptake inhibitor formulations |
| EP1250937B1 (en) * | 2001-04-09 | 2009-05-13 | Rohm And Haas Company | Controlled dissolution of active ingredients |
| US20020176842A1 (en) * | 2001-04-09 | 2002-11-28 | Lyn Hughes | Extended release of active ingredients |
| US6906206B2 (en) * | 2001-04-30 | 2005-06-14 | Wyeth | Antidepressant azaheterocyclylmethyl derivatives of 1,4,5-trioxa-phenanthrene |
| DE60210308T2 (de) * | 2001-08-09 | 2006-11-30 | Smithkline Beecham P.L.C., Brentford | Zusammensetzung enthaltend paroxetin und ein pharmazeutisch verträgliches salz von glycyrrhizinsäure |
| GB0119467D0 (en) * | 2001-08-09 | 2001-10-03 | Smithkline Beecham Plc | Novel compound |
| US6939877B2 (en) * | 2002-09-12 | 2005-09-06 | Wyeth | Antidepressant piperidine derivatives of heterocycle-fused benzodioxans |
| US20040220153A1 (en) * | 2002-09-24 | 2004-11-04 | Jost-Price Edward Roydon | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
| US20050036977A1 (en) * | 2003-08-11 | 2005-02-17 | Dilip Gole | Taste-masked resinate and preparation thereof |
| US20050266082A1 (en) * | 2004-05-26 | 2005-12-01 | Patel Satishkumar A | Preparation of stable paroxetine HC1 ER tablets using a melt granulation process |
| WO2006018318A1 (en) * | 2004-08-18 | 2006-02-23 | Synthon B.V. | Liquid paroxetine compositions |
| US20060039975A1 (en) * | 2004-08-20 | 2006-02-23 | Zalman Vilkov | Paroxetine formulations |
| KR100672184B1 (ko) * | 2004-09-21 | 2007-01-19 | 주식회사종근당 | 파록세틴의 콜린산 또는 콜린산 유도체 염 |
| CA2629514A1 (en) * | 2005-11-14 | 2007-05-24 | Auspex Pharmaceuticals, Inc. | Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties |
| CN102430122A (zh) * | 2005-12-13 | 2012-05-02 | 量子高科（北京）研究院有限公司 | 盐酸氟西汀口腔崩解片及其制备方法 |
| FR2912057B1 (fr) * | 2007-02-07 | 2009-04-17 | Sanofi Aventis Sa | Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine |
| TW200817003A (en) * | 2006-07-31 | 2008-04-16 | Sanofi Aventis | Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor |
| US20100273822A1 (en) * | 2009-04-22 | 2010-10-28 | William Wayne Howard | Immediate release compositions and methods for delivering drug formulations using strong acid ion exchange resins |
| WO2010150219A1 (en) * | 2009-06-25 | 2010-12-29 | Wockhardt Research Centre | Pharmaceutical composition of duloxetine or pharmaceutically acceptable salts thereof |
| US8187617B2 (en) * | 2009-09-11 | 2012-05-29 | William Wayne Howard | Immediate release compositions and methods for delivering drug formulations using weak acid ion exchange resins in abnormally high pH environments |
| MX2012013328A (es) | 2010-05-19 | 2013-02-01 | Astellas Pharma Inc | Composicion farmaceutica que contiene solifenacina. |
| CN104027306A (zh) * | 2014-06-25 | 2014-09-10 | 万特制药(海南)有限公司 | 帕罗西汀口服混悬液及其制备方法 |
| GB201419261D0 (en) * | 2014-10-29 | 2014-12-10 | Therakind Ltd | Formulations |
| CN104382870A (zh) * | 2014-10-30 | 2015-03-04 | 万全万特制药江苏有限公司 | 一种含有波拉克林钾-帕罗西汀的复合物 |
| CN106309363A (zh) * | 2016-09-24 | 2017-01-11 | 万特制药(海南)有限公司 | 盐酸帕罗西汀口服混悬液及其制备方法 |
| CN108926528A (zh) * | 2017-05-25 | 2018-12-04 | 北京万全德众医药生物技术有限公司 | 含有氨磺必利树脂酸盐的口服液体组合物 |
| EP3917523A4 (en) | 2019-02-01 | 2022-10-19 | University of South Carolina | BICYCLIC PYRIDINE COMPOSITIONS AND METHODS OF USE THERE FOR CANCER THERAPY |
| CN113209017B (zh) * | 2021-06-02 | 2023-06-20 | 上海美优制药有限公司 | 一种盐酸帕罗西汀混悬剂及其制备方法 |
| GB202212116D0 (en) | 2022-08-19 | 2022-10-05 | Beckley Psytech Ltd | Pharmaceutically acceptable salts and Compositions thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1422263A (en) * | 1973-01-30 | 1976-01-21 | Ferrosan As | 4-phenyl-piperidine compounds |
| GB9005498D0 (en) * | 1990-03-12 | 1990-05-09 | Beecham Group Plc | Composition |
| IT1246188B (it) * | 1990-07-27 | 1994-11-16 | Resa Farma | Procedimento per la preparazione di composizioni farmaceutiche aventi aumentata velocita' di dissoluzione della sostanza attiva e composizioni ottenute. |
-
1994
- 1994-02-03 GB GB9402029A patent/GB9402029D0/en active Pending
-
1995
- 1995-01-27 MY MYPI95000223A patent/MY113036A/en unknown
- 1995-01-30 HU HU9602151A patent/HUT75941A/hu unknown
- 1995-01-30 SK SK1004-96A patent/SK281214B6/sk unknown
- 1995-01-30 NZ NZ278891A patent/NZ278891A/en not_active IP Right Cessation
- 1995-01-30 ES ES95906998T patent/ES2129806T3/es not_active Expired - Lifetime
- 1995-01-30 CN CN95191483A patent/CN1074922C/zh not_active Expired - Fee Related
- 1995-01-30 JP JP52037095A patent/JP4445590B2/ja not_active Expired - Lifetime
- 1995-01-30 RO RO96-01580A patent/RO116342B1/ro unknown
- 1995-01-30 WO PCT/EP1995/000319 patent/WO1995020964A1/en active IP Right Grant
- 1995-01-30 DK DK95906998T patent/DK0742715T3/da active
- 1995-01-30 PL PL95315679A patent/PL178331B1/pl not_active IP Right Cessation
- 1995-01-30 RU RU96117470/14A patent/RU2136281C1/ru not_active IP Right Cessation
- 1995-01-30 AU AU15368/95A patent/AU682091B2/en not_active Expired
- 1995-01-30 AT AT95906998T patent/ATE178489T1/de active
- 1995-01-30 US US08/682,799 patent/US5811436A/en not_active Expired - Lifetime
- 1995-01-30 MX MX9603203A patent/MX9603203A/es unknown
- 1995-01-30 CZ CZ962293A patent/CZ285128B6/cs unknown
- 1995-01-30 EP EP95906998A patent/EP0742715B1/en not_active Expired - Lifetime
- 1995-01-30 BR BR9507055A patent/BR9507055A/pt not_active IP Right Cessation
- 1995-01-30 CA CA002182593A patent/CA2182593A1/en not_active Abandoned
- 1995-01-30 AP APAP/P/1996/000839A patent/AP611A/en active
- 1995-01-30 DE DE69508924T patent/DE69508924T2/de not_active Expired - Lifetime
- 1995-02-01 ZA ZA95776A patent/ZA95776B/xx unknown
- 1995-02-01 DZ DZ950010A patent/DZ1850A1/fr active
- 1995-02-01 AP APAP/P/1995/000715A patent/AP536A/en active
- 1995-02-01 MA MA23768A patent/MA23441A1/fr unknown
- 1995-02-02 IL IL11252195A patent/IL112521A/xx not_active IP Right Cessation
- 1995-02-09 TW TW084101235A patent/TW436296B/zh active
-
1996
- 1996-08-01 BG BG100763A patent/BG62843B1/bg unknown
- 1996-08-01 FI FI963051A patent/FI118205B/fi not_active IP Right Cessation
- 1996-08-02 OA OA60873A patent/OA10446A/en unknown
- 1996-08-02 NO NO963244A patent/NO307954B1/no not_active IP Right Cessation
-
1998
- 1998-12-16 HK HK98113631A patent/HK1012288A1/xx not_active IP Right Cessation
-
1999
- 1999-04-30 GR GR990401213T patent/GR3030131T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HU9602151D0 (en) | Oral liquid compositions containing paroxetine resinate | |
| PL319355A1 (en) | Oral compositions | |
| PL322136A1 (en) | Oral compositions | |
| KR970700481A (en) | Oral composition | |
| AU2372095A (en) | Oral compositions | |
| GB9513694D0 (en) | Oral compositions | |
| GB9425934D0 (en) | Oral compositions | |
| ZA955519B (en) | Oral compositions | |
| GB9515597D0 (en) | Oral compositions | |
| GB9412048D0 (en) | Oral hygiene composition | |
| PL320866A1 (en) | Oral compositions | |
| HU9500618D0 (en) | Oral pharmaceutical compositions | |
| AU2427895A (en) | Oral compositions | |
| GB2307640B (en) | Oral hygiene composition | |
| GB9500746D0 (en) | Oral compositions | |
| HUP9801706A3 (en) | Oral compositions | |
| HUP0101931A3 (en) | Novel formulation containing paroxetine | |
| GB9425933D0 (en) | Oral compositions | |
| SI0742715T1 (en) | Oral liquid compositions containing paroxetine resinate | |
| IL139594A0 (en) | Novel formulation containing paroxetine | |
| GB2285923B (en) | Pharmaceutical compositions containing N-acetal-cysteine | |
| GB9510328D0 (en) | Compositions containing zirconium compounds | |
| GB9417357D0 (en) | Dental compositions | |
| IL107417A0 (en) | Liquid dental compositions | |
| GB9513693D0 (en) | Oral compositions |